HK1134305A1 - Method using a transgenic animal with enhanced immune response - Google Patents

Method using a transgenic animal with enhanced immune response

Info

Publication number
HK1134305A1
HK1134305A1 HK10102268.9A HK10102268A HK1134305A1 HK 1134305 A1 HK1134305 A1 HK 1134305A1 HK 10102268 A HK10102268 A HK 10102268A HK 1134305 A1 HK1134305 A1 HK 1134305A1
Authority
HK
Hong Kong
Prior art keywords
immune response
enhanced
animal
human animal
transgenic animal
Prior art date
Application number
HK10102268.9A
Other languages
English (en)
Inventor
Zsuzsanna Boesze
Imre Kacskovics
Judit Cervenak
Laszlo Hiripi
Balazs Bender
Original Assignee
Agricultural Biotechnology Ct
Eoetvoes Lorand University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1134305(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from HUE06000870 external-priority patent/HU0600870D0/hu
Application filed by Agricultural Biotechnology Ct, Eoetvoes Lorand University filed Critical Agricultural Biotechnology Ct
Publication of HK1134305A1 publication Critical patent/HK1134305A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK10102268.9A 2006-11-24 2010-03-03 Method using a transgenic animal with enhanced immune response HK1134305A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUE06000870 HU0600870D0 (en) 2006-11-24 2006-11-24 Transgenic animal with increased immunoglobulin level and method for the preparation thereof
HUE07000534 2007-08-14
PCT/IB2007/054770 WO2008062383A2 (fr) 2006-11-24 2007-11-23 Animal transgénique présentant une réponse immunitaire améliorée et procédé d'élaboration correspondant

Publications (1)

Publication Number Publication Date
HK1134305A1 true HK1134305A1 (en) 2010-04-23

Family

ID=46846408

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10102268.9A HK1134305A1 (en) 2006-11-24 2010-03-03 Method using a transgenic animal with enhanced immune response

Country Status (12)

Country Link
US (2) US20100041743A1 (fr)
EP (3) EP2559701B1 (fr)
JP (2) JP5752355B2 (fr)
CN (1) CN101595128B (fr)
AT (1) ATE513852T1 (fr)
AU (2) AU2007323049B2 (fr)
CA (1) CA2670389C (fr)
DK (1) DK2097444T3 (fr)
HK (1) HK1134305A1 (fr)
HU (1) HU0700534D0 (fr)
PL (1) PL2097444T3 (fr)
WO (1) WO2008062383A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181690A1 (en) * 2009-12-21 2012-07-30 Regeneron Pharma Humanized fcy r mice
ES2914374T3 (es) 2011-10-28 2022-06-10 Regeneron Pharma Ratones modificados genéticamente que expresan moléculas quiméricas del complejo de histocompatibilidad mayor (MHC) de clase II
WO2013067328A1 (fr) * 2011-11-03 2013-05-10 University Of Iowa Research Foundation Modèles de la mucoviscidose sur cochons transgéniques
CA2900824A1 (fr) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Souris exprimant un complexe majeur d'histocompatibilite
WO2015036004A1 (fr) * 2013-09-13 2015-03-19 Immunogenes Ag Procédé de préparation d'une composition d'atg améliorée
CN104237533A (zh) * 2014-09-23 2014-12-24 中国科学院东北地理与农业生态研究所 一种初步筛选可用于繁殖后代转基因母羊的方法
CN114410643A (zh) * 2021-02-02 2022-04-29 百奥赛图(北京)医药科技股份有限公司 FcRn基因人源化的非人动物及其构建方法和应用
CN116076438B (zh) * 2023-03-21 2024-01-30 湖南中医药大学 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690956B2 (ja) 1987-08-22 1997-12-17 三井東圧化学株式会社 生体由来のタンパク質
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5675063A (en) * 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU9484798A (en) * 1997-09-11 1999-03-29 Public Health Research Institute Of The City Of New York, Inc., The Enhancement of mucosal antibody responses by interleukin-6
US6249816B1 (en) * 1998-07-22 2001-06-19 Nokia Telecommunications, Oy NBR pool for SIMA network
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
AU781544B2 (en) * 2000-02-03 2005-05-26 Lennart Hammarstrom Ruminant MHC class I-like Fc receptors
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
WO2005005636A1 (fr) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha Production d'igm par une cellule transformee et procede de quantification de cette derniere
CN1930188B (zh) 2004-03-10 2012-01-11 克赖顿大学 雌激素受体和使用方法
CA2616069C (fr) 2005-08-03 2018-07-31 Therapeutic Human Polyclonals, Inc. Suppression de l'apoptose des lymphocytes b chez les animaux transgeniques exprimant une immunoglobuline humanisee
EP1790716A1 (fr) 2005-11-23 2007-05-30 UMC Utrecht Holding B.V. Utilisations du récepteur Fc néonatal

Also Published As

Publication number Publication date
WO2008062383A2 (fr) 2008-05-29
AU2012203243A1 (en) 2012-06-21
AU2007323049B2 (en) 2012-03-15
CN101595128A (zh) 2009-12-02
PL2097444T3 (pl) 2011-11-30
US20130109087A1 (en) 2013-05-02
JP2013215194A (ja) 2013-10-24
DK2097444T3 (da) 2011-08-29
CN101595128B (zh) 2014-11-26
AU2007323049A8 (en) 2011-07-28
EP2097444B1 (fr) 2011-06-22
EP2097444A2 (fr) 2009-09-09
ATE513852T1 (de) 2011-07-15
JP2010510773A (ja) 2010-04-08
US20100041743A1 (en) 2010-02-18
WO2008062383A3 (fr) 2008-08-14
EP2386573A1 (fr) 2011-11-16
CA2670389A1 (fr) 2008-05-29
AU2007323049A1 (en) 2008-05-29
JP5752355B2 (ja) 2015-07-22
CA2670389C (fr) 2014-12-09
EP2559701B1 (fr) 2016-04-20
HU0700534D0 (en) 2007-10-29
EP2559701A1 (fr) 2013-02-20

Similar Documents

Publication Publication Date Title
HK1134305A1 (en) Method using a transgenic animal with enhanced immune response
WO2007117410A3 (fr) Animaux transgéniques exprimant des anticorps chimériques destinés à être utilisés pour la préparation d'anticorps humains
ES2849349T3 (es) Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos
SG10201408500RA (en) Antibody producing non-human mammals
ECSP12011698A (es) Anticuerpos cea
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
JP2020078350A (ja) ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物
LTPA2017022I1 (lt) Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas
CR9236A (es) Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas
WO2003064606A3 (fr) Anticorps monoclonaux humains de l'antigene d'enveloppe prostatique specifique (psma)
HK1118458A1 (en) Anti-il-23 antibodies, compositions, methods and uses
WO2006047367A3 (fr) Suppression de l'expression d'immunoglobulines endogenes
US9557323B2 (en) Humanized transgenic mouse model
BR112014009941A2 (pt) camundongos transgênicos expressando moléculas do complexo de histocompatibilidade principal (mhc) quimérico classe ii
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
WO2008153743A3 (fr) Compositions et procédés permettant de rechercher des gènes du cancer
MX345224B (es) Proteinas cry insecticidas cry1ca modificadas.
CN103571872A (zh) 一种能够表达人抗体的转基因动物的制备方法
PT1709073E (pt) Substância que se liga ao receptor fc iib de igg humano (fcgamariib)
Kacskovics et al. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies
DE602005026688D1 (de) Toleranzstudienverfahren bei mhc-ii-transgenen tieren
SG142293A1 (en) Method for producing anti-idiotypic antibodies
WO2006136951A3 (fr) Cellules souches de souris et applications associees
ATE432944T1 (de) Varianten der gruppe 1-allergene aus poaceae mit reduzierter allergenität und erhaltener t- zellreaktivität

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221123